Prognostic factors for patients with anti-melanoma differentiation-associated gene 5 (MDA-5) antibody positive idiopathic inflammatory myopathy (IIM) associated interstitial lung disease (ILD): a single centor retrospective cohort study

Prognostic factors for patients with anti-melanoma differentiation-associated gene 5 (MDA-5) antibody positive idiopathic inflammatory myopathy (IIM) associated interstitial lung disease (ILD): a single centor retrospective cohort study - Not applicable

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042731

Enrollment

Registered

2020-12-16

Start date

2010-01-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anti-MDA-5 antibody-positive patients with IIM associated ILD

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: MDA-5 antibody positive IIM associated ILD

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
Mortality at 12 months	—

Secondary

Measure	Time frame
Mortality at 3months, 6 months, and 24 months	—

Countries

Japan

Contacts

Public ContactRyo Yanai

Showa University Division of Rheumatology, Department of Medicine

ryo.yanai@med.showa-u.ac.jp+81-3-3784-8942

Outcome results